Loading…

Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death

Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ke...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2002-04, Vol.72 (3), p.265-278
Main Authors: ZHANG, Yicheng, CRUMP, Michael, BERGER, Stuart A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33
cites cdi_FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33
container_end_page 278
container_issue 3
container_start_page 265
container_title Breast cancer research and treatment
container_volume 72
creator ZHANG, Yicheng
CRUMP, Michael
BERGER, Stuart A
description Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ketotifen for 24 h underwent a dose-dependent, irreversible loss of viability, and clonogenicity. Two-hour treatment of these cells with higher concentrations of the drugs also resulted in loss of clonogenicity, but morphological indicators of cell death were apparent only after longer incubation. Loss of clonogenicity could be enhanced almost 10-fold by co-stimulation of the cells with the agonists EGF or bombesin. Econazole was also effective in inducing cell death in multi-drug resistant MCF-7adr cells. Human hemopoietic progenitor cell sensitivity to econazole or ketotifen was evaluated by colony assay. Under conditions resulting in 2.5-3 logs of breast cancer cell loss, 60-70% of hemopoietic progenitors could be recovered. We further evaluated the effect of econazole on breast cancer cells present in mobilized hemopoietic cells obtained from patients undergoing high dose chemotherapy with autologous stem cell support. In six of eight samples evaluated, cytokeratin-positive breast cancer cells could be detected by immunofluorescence microscopy and colony formation. Breast cancer colonies were reduced 60-500-fold or more after exposure to econazole while hemopoietic colonies were typically reduced only 2-fold. In all cases, addition of EGF as an activator either had no evaluable effect or enhanced breast cancer cell loss. We conclude that Ca2+ influx blockade with concurrent EGF stimulation is a promising approach for purging breast cancer cells from hemopoietic progenitor cell preparations.
doi_str_mv 10.1023/A:1014965726663
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71808871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71808871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33</originalsourceid><addsrcrecordid>eNpdkU2LFDEQhoMo7uzq2ZsEwb21m3S6k463YfELFvSg56Y6qcxkmU7GJL3g0X9u2hlY9BRSPPXwUi8hrzh7x1krbrbvOeOdlr1qpZTiCdnwXolGtVw9JRvGpWrkwOQFucz5njGmFdPPyQVvWT9oOWzI729L2vmwo9FRE0OB2Qco62BKCLlQA8FgogYPh0xdijPd4wwlHqPH4g09prjD4Es8MfWPR0hVEUOmS15NYIp_-DuhGParz55Yi1D2L8gzB4eML8_vFfnx8cP328_N3ddPX263d40RmpfGgEU5OOS6RS6cE7pXkttJOistMOMsmAGcFq61mulhUMzipKVRrkc1CXFFrk_emvjngrmMs89rDAgYlzwqPrC6xSv45j_wPi4p1Gxjy9uuY6xboZsTZFLMOaEbj8nPkH6NnI1rNeN2_KeauvH6rF2mGe0jf-6iAm_PAGQDB5fqpXx-5IQUXae1-ANsNJmk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212440041</pqid></control><display><type>article</type><title>Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death</title><source>Springer Nature</source><creator>ZHANG, Yicheng ; CRUMP, Michael ; BERGER, Stuart A</creator><creatorcontrib>ZHANG, Yicheng ; CRUMP, Michael ; BERGER, Stuart A</creatorcontrib><description>Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ketotifen for 24 h underwent a dose-dependent, irreversible loss of viability, and clonogenicity. Two-hour treatment of these cells with higher concentrations of the drugs also resulted in loss of clonogenicity, but morphological indicators of cell death were apparent only after longer incubation. Loss of clonogenicity could be enhanced almost 10-fold by co-stimulation of the cells with the agonists EGF or bombesin. Econazole was also effective in inducing cell death in multi-drug resistant MCF-7adr cells. Human hemopoietic progenitor cell sensitivity to econazole or ketotifen was evaluated by colony assay. Under conditions resulting in 2.5-3 logs of breast cancer cell loss, 60-70% of hemopoietic progenitors could be recovered. We further evaluated the effect of econazole on breast cancer cells present in mobilized hemopoietic cells obtained from patients undergoing high dose chemotherapy with autologous stem cell support. In six of eight samples evaluated, cytokeratin-positive breast cancer cells could be detected by immunofluorescence microscopy and colony formation. Breast cancer colonies were reduced 60-500-fold or more after exposure to econazole while hemopoietic colonies were typically reduced only 2-fold. In all cases, addition of EGF as an activator either had no evaluable effect or enhanced breast cancer cell loss. We conclude that Ca2+ influx blockade with concurrent EGF stimulation is a promising approach for purging breast cancer cells from hemopoietic progenitor cell preparations.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1023/A:1014965726663</identifier><identifier>PMID: 12058968</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Bone Marrow Purging ; Breast cancer ; Breast Neoplasms - therapy ; Cancer research ; Cancer therapies ; Cell death ; Cell Death - drug effects ; Colony-Forming Units Assay ; Econazole ; Female ; General aspects ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells - drug effects ; Humans ; Ketotifen ; Medical sciences ; Pharmacology. Drug treatments ; Tumor Cells, Cultured</subject><ispartof>Breast cancer research and treatment, 2002-04, Vol.72 (3), p.265-278</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Mar 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33</citedby><cites>FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13634499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12058968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZHANG, Yicheng</creatorcontrib><creatorcontrib>CRUMP, Michael</creatorcontrib><creatorcontrib>BERGER, Stuart A</creatorcontrib><title>Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ketotifen for 24 h underwent a dose-dependent, irreversible loss of viability, and clonogenicity. Two-hour treatment of these cells with higher concentrations of the drugs also resulted in loss of clonogenicity, but morphological indicators of cell death were apparent only after longer incubation. Loss of clonogenicity could be enhanced almost 10-fold by co-stimulation of the cells with the agonists EGF or bombesin. Econazole was also effective in inducing cell death in multi-drug resistant MCF-7adr cells. Human hemopoietic progenitor cell sensitivity to econazole or ketotifen was evaluated by colony assay. Under conditions resulting in 2.5-3 logs of breast cancer cell loss, 60-70% of hemopoietic progenitors could be recovered. We further evaluated the effect of econazole on breast cancer cells present in mobilized hemopoietic cells obtained from patients undergoing high dose chemotherapy with autologous stem cell support. In six of eight samples evaluated, cytokeratin-positive breast cancer cells could be detected by immunofluorescence microscopy and colony formation. Breast cancer colonies were reduced 60-500-fold or more after exposure to econazole while hemopoietic colonies were typically reduced only 2-fold. In all cases, addition of EGF as an activator either had no evaluable effect or enhanced breast cancer cell loss. We conclude that Ca2+ influx blockade with concurrent EGF stimulation is a promising approach for purging breast cancer cells from hemopoietic progenitor cell preparations.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Purging</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Cell Death - drug effects</subject><subject>Colony-Forming Units Assay</subject><subject>Econazole</subject><subject>Female</subject><subject>General aspects</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Humans</subject><subject>Ketotifen</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Cells, Cultured</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpdkU2LFDEQhoMo7uzq2ZsEwb21m3S6k463YfELFvSg56Y6qcxkmU7GJL3g0X9u2hlY9BRSPPXwUi8hrzh7x1krbrbvOeOdlr1qpZTiCdnwXolGtVw9JRvGpWrkwOQFucz5njGmFdPPyQVvWT9oOWzI729L2vmwo9FRE0OB2Qco62BKCLlQA8FgogYPh0xdijPd4wwlHqPH4g09prjD4Es8MfWPR0hVEUOmS15NYIp_-DuhGParz55Yi1D2L8gzB4eML8_vFfnx8cP328_N3ddPX263d40RmpfGgEU5OOS6RS6cE7pXkttJOistMOMsmAGcFq61mulhUMzipKVRrkc1CXFFrk_emvjngrmMs89rDAgYlzwqPrC6xSv45j_wPi4p1Gxjy9uuY6xboZsTZFLMOaEbj8nPkH6NnI1rNeN2_KeauvH6rF2mGe0jf-6iAm_PAGQDB5fqpXx-5IQUXae1-ANsNJmk</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>ZHANG, Yicheng</creator><creator>CRUMP, Michael</creator><creator>BERGER, Stuart A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20020401</creationdate><title>Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death</title><author>ZHANG, Yicheng ; CRUMP, Michael ; BERGER, Stuart A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Purging</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Cell Death - drug effects</topic><topic>Colony-Forming Units Assay</topic><topic>Econazole</topic><topic>Female</topic><topic>General aspects</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Humans</topic><topic>Ketotifen</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZHANG, Yicheng</creatorcontrib><creatorcontrib>CRUMP, Michael</creatorcontrib><creatorcontrib>BERGER, Stuart A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZHANG, Yicheng</au><au>CRUMP, Michael</au><au>BERGER, Stuart A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>72</volume><issue>3</issue><spage>265</spage><epage>278</epage><pages>265-278</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ketotifen for 24 h underwent a dose-dependent, irreversible loss of viability, and clonogenicity. Two-hour treatment of these cells with higher concentrations of the drugs also resulted in loss of clonogenicity, but morphological indicators of cell death were apparent only after longer incubation. Loss of clonogenicity could be enhanced almost 10-fold by co-stimulation of the cells with the agonists EGF or bombesin. Econazole was also effective in inducing cell death in multi-drug resistant MCF-7adr cells. Human hemopoietic progenitor cell sensitivity to econazole or ketotifen was evaluated by colony assay. Under conditions resulting in 2.5-3 logs of breast cancer cell loss, 60-70% of hemopoietic progenitors could be recovered. We further evaluated the effect of econazole on breast cancer cells present in mobilized hemopoietic cells obtained from patients undergoing high dose chemotherapy with autologous stem cell support. In six of eight samples evaluated, cytokeratin-positive breast cancer cells could be detected by immunofluorescence microscopy and colony formation. Breast cancer colonies were reduced 60-500-fold or more after exposure to econazole while hemopoietic colonies were typically reduced only 2-fold. In all cases, addition of EGF as an activator either had no evaluable effect or enhanced breast cancer cell loss. We conclude that Ca2+ influx blockade with concurrent EGF stimulation is a promising approach for purging breast cancer cells from hemopoietic progenitor cell preparations.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>12058968</pmid><doi>10.1023/A:1014965726663</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6806
ispartof Breast cancer research and treatment, 2002-04, Vol.72 (3), p.265-278
issn 0167-6806
1573-7217
language eng
recordid cdi_proquest_miscellaneous_71808871
source Springer Nature
subjects Antineoplastic agents
Biological and medical sciences
Bone Marrow Purging
Breast cancer
Breast Neoplasms - therapy
Cancer research
Cancer therapies
Cell death
Cell Death - drug effects
Colony-Forming Units Assay
Econazole
Female
General aspects
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells - drug effects
Humans
Ketotifen
Medical sciences
Pharmacology. Drug treatments
Tumor Cells, Cultured
title Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T08%3A44%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Purging%20of%20contaminating%20breast%20cancer%20cells%20from%20hematopoietic%20progenitor%20cell%20preparations%20using%20activation%20enhanced%20cell%20death&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=ZHANG,%20Yicheng&rft.date=2002-04-01&rft.volume=72&rft.issue=3&rft.spage=265&rft.epage=278&rft.pages=265-278&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1023/A:1014965726663&rft_dat=%3Cproquest_cross%3E71808871%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-cade68fe192e13ff395761db6fd6da0cfdac8af93f2d9098870deb96c7f5e7b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212440041&rft_id=info:pmid/12058968&rfr_iscdi=true